In an expert interview at ESMO 2018, Dr András Illés discusses the current research behind RGB-02, a biosimilar pegfilgrastim for the treatment of chemotherapy-induced neutropenia. Biosimilars are subjected to rigorous clinical trials to ensure equivalence to the originator drug in terms of safety...
